Full-Time
Territory Sales Specialist
Pediatrics
Confirmed live in the last 24 hours
Azurity Pharmaceuticals
201-500 employees
Develops specialized formulations of medicines
Junior, Mid
Phoenix, AZ, USA
Hybrid work model: 2 days in office, 3 days from home.
You match the following Azurity Pharmaceuticals's candidate preferences
Employers are more likely to interview you if you match these preferences:
- Bachelor’s degree
- At least 2 years of Pharmaceutical or Healthcare Industry sales experience
- Demonstrated growth in sales while managing your own territory – track record of consistently meeting or exceeding sales goals
- Business acumen, comprehension of clinical information, and ability to articulate a clinical sales message to Healthcare Providers
- Excellent organization and time management skills
- Outstanding oral and written communication skills
- Strong interpersonal and virtual engagement skills
- Ability to work with a CRM tool (i.e., Veeva)
- Independent, with an ability to work within a team
- Attention to detail and follow-through
- Proficient in Microsoft Office (Word, Excel, PPT, etc.)
- Develop and execute a strategic business plan for a geographical area to effectively target, penetrate, and establish a network of relationships with key decision makers and stakeholders
- Effectively call on physicians, nurses, nurse practitioners, physician assistants, etc., across multiple medical subspecialties
- Manage hybrid relationships through a mix of in-person and virtual engagement – being able to leverage next gen ways of working to maximize efficiency
- Effectively call on retail pharmacies, both chain and independent
- Utilize data sources to maximize strategies and efficiencies to capitalize on opportunities with the greatest ROI
- Attain or exceed assigned sales and profit goal
- Manage and track territory specific information through a CRM system
Azurity Pharmaceuticals develops specialized formulations of existing medicines to meet the needs of patients who are often overlooked by other pharmaceutical companies. Their products include oral suspensions and other dose forms that are easier to administer, particularly for those who have difficulty swallowing pills or need precise dosing. This focus on creating accessible and effective medications enhances patient compliance and addresses gaps in the pharmaceutical market. Azurity serves healthcare providers, hospitals, and pharmacies, generating revenue through the sale of FDA-approved proprietary medicines across various therapeutic areas, including cardiovascular, central nervous system, and oncology. Their goal is to improve patient outcomes by providing high-quality, innovative medicines tailored to specific medical conditions.
Company Size
201-500
Company Stage
Growth Equity (Venture Capital)
Total Funding
$182.2M
Headquarters
Woburn, Massachusetts
Founded
2000
Simplify's Take
What believers are saying
- Growing demand for personalized medicine aligns with Azurity's specialized dose forms.
- Increasing chronic diseases boost need for Azurity's innovative drug delivery systems.
- FDA's focus on novel formulations benefits Azurity's product pipeline.
What critics are saying
- Product recalls, like Zenzedi's, can damage brand reputation and cause financial losses.
- Integration challenges from Slayback Pharma acquisition may disrupt operations.
- Reliance on FDA approvals means regulatory delays could impact product launches.
What makes Azurity Pharmaceuticals unique
- Azurity focuses on innovative dose forms for overlooked patient needs.
- Their FDA-approved products ensure safety and efficacy in specialized formulations.
- Azurity's acquisition of Slayback Pharma enhances its development and launch capabilities.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Hybrid Work Options
Professional Development Budget
Tuition Reimbursement
Wellness Program
Company News
WOBURN, Mass., Dec. 12, 2024 /PRNewswire/ -- Azurity Pharmaceuticals announced today the availability of Azmiro™, the first and only FDA-approved prefilled testosterone cypionate injection. Azmiro is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. "Azurity's purpose is to serve overlooked patients by developing innovative dose forms and formulations to serve unmet needs," said Richard Blackburn, CEO of Azurity Pharmaceuticals. "The commercial availability of Azmiro offers a convenient prefilled option for healthcare providers administering testosterone to patients.". Testosterone cypionate intramuscular injections are commonly used as a testosterone replacement therapy for patients with low testosterone by drawing up testosterone cypionate doses from a vial, then administering with a syringe
WOBURN, Mass., Dec. 12, 2024 /PRNewswire/ - Azurity Pharmaceuticals announced today the availability of Azmiro(TM), the first and only FDA-approved prefilled testosterone cypionate injection.
WOBURN, Mass., May 6, 2024 /PRNewswire/ -- Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced today that the U.S. Food and Drug Administration (FDA) has approved Myhibbin™, the only ready-to-use mycophenolate mofetil oral suspension. Mycophenolate mofetil is an antimetabolite immunosuppressant used to protect a donated organ from being rejected from the body's immune response. In 2023, there were over 46,000 transplants in the US and these patients need to take medication every day to fight against rejection. Myhibbin is indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart, or liver transplants, in combination with other immunosuppressants."We are very pleased that adult and pediatric organ transplant recipients will soon have access to the only FDA-approved ready-to-use oral liquid formulation of mycophenolate," said Richard Blackburn, CEO of Azurity Pharmaceuticals. "Patients are our priority, and our purpose is to bring them new formulations that help them benefit from established medicines
Azurity Pharmaceuticals issued a recall for attention-deficit/hyperactivity disorder (ADHD) medication dextroamphetamine sulfate (Zenzedi) following the discovery of a potential mix-up in pill packaging, according to CNN.
Azurity Pharmaceuticals, Inc. announced the recall of one lot (F230169A) of Zenzedi CII (dextroamphetamine sulfate tablets, USP) 30 milligrams on Wednesday, which the U.S. Food and Drug Administration (FDA) put on its website on Thursday.
Drug mix-up prompts Azurity to recall 1 batch of narcolepsy drug Zenzedi.
WOBURN, Ma., Sept. 27, 2023 /PRNewswire/ -- Azurity Pharmaceuticals, Inc. ("Azurity") is pleased to announce the closing of its acquisition of Slayback Pharma LLC ("Slayback") today from existing investors including KKR, a leading global investment firm, and Everstone Capital. Slayback is now a wholly-owned subsidiary of Azurity.The acquisition brings together companies with complementary strengths, enhancing Azurity's ability to realize its purpose of Serving Overlooked Patients. The combined development portfolios are expected to yield a significant number of new medicine launches over the coming years.Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust pipeline. The company's patient-centric approach is evident in its diverse array of products catering to various medical needs, including cardiovascular, central nervous system, endocrinological, gastrointestinal, anti-infectives and oncology
In December, Azurity Pharmaceuticals launched EPRONTIA, the first and only liquid formulation of topiramate.
Azurity Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing innovative medicines that meet the specific needs of underserved patient segments, announced Richard Blackburn has been appointed Chief Executive Officer, effective February 14, 2022.
Azurity had purchased zonisamide oral suspension from Eton Pharmaceuticals, Inc.